Skip to main content


Presenter: Athimalaipet Ramanan, University Hospitals Bristol NHS Foundation Trust, UK.

Saturday 15 June: 08:00–09:00 (Abstract LB0011)

APTITUDE is a single-arm phase II trial investigating the efficacy and safety profiles of the interleukin-6 inhibitor tocilizumab, given alongside methotrexate, in children and adolescents with juvenile idiopathic arthritis-associated uveitis. The primary endpoint is response according to the SUN criteria after 12 weeks of treatment.

More on this trial